Biomarker panel for diagnosing colorectal cancer
The invention offers a plasma protein biomarker set that can be used as a diagnostic tool for diagnosis and stratification of colorectal cancer.
Sigmoidoscopy and colonoscopy, the current gold standards for detection of CRC in the distal and total colorectum, respectively, are limited by several disadvantages, such as high costs, limited resources and poor compliance. So other cost effective and sensitive methods for the early detection of colorectal cancer are urgently needed and very important from the health economic standpoint. The invention offers a plasma protein biomarker set that can be used as a diagnostic tool for diagnosis and stratification of colorectal cancer.
Based on the prospective BliTz study from 2005– 2012 including approximately 5500 participants a panel of 17 plasma proteins was identified by analysis of 35 CRC patients who were compared to a representative sample of 54 controls free of colorectal neoplasms. This set was further reduced to a core panel of 8 proteins without substantial loss of predictive power.
High costs, limited resources and poor compliance of the current gold standards for detection of CRC.
An enhanced detection tool CRC from the health economic standpoint.
Core set of 8 protein markers performing with an AUC [95% CI] of 0.76 [0.65–0.85] / specificity of 44% [24–72%] and a sensitivity of 90%.
DKFZ is looking for a commercial partner for further development of the marker panel alone or in combination with other markers towards clinical application.
Publikationen & Verweise
Head-to-Head Comparison and Evaluation of 92 Plasma Protein Biomarkers for Early Detection of Colorectal Cancer in a True Screening Setting. Chen H. et al. Clin Cancer Res. 2015 Jul 15;21(14):3318-26. See at: www.ncbi.nlm.nih.gov/pubmed/;
Weitere Information zum Herunterladen
- 213 Ki